WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Protalix Biotherapeutics earnings were $18.9M for the trailing 12 months ending Jun 30, 2026, with 200% growth year over year. The latest PLX earnings report on Jun 30, 2026 announced Q2 2026 earnings of $3.8M, down 79.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PLX reported annual earnings of -$6.6M, with -325.2% growth.

PLX past earnings growth

How has PLX's earnings growth performed historically?

Company
200%
Industry
17.19%
Market
93.08%
PLX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PLX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
PLX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

PLX earnings history

Current Revenue
$80.6M
Current Earnings
$18.9M
Current Profit Margin
23.5%
PLX's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

PLX Return on Equity

Current Company
31.6%
Current Industry
-13.6%
Current Market
33%
PLX's Return on Equity (31.6%)... subscribe to Premium to read more.
High Return on Equity Performance

PLX Return on Assets

Current Company
20.1%
Current Industry
-10.2%
PLX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PLX announces earnings.

PLX Return on Capital Employed

Current Company
31.31%
Current Industry
-6.7%
PLX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PLX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PLX$26.28M$18.95M+111.87%$0.24
PEPG-$70.61M-$71.94MN/A-$1.02
CRBP-$101.70M-$101.90MN/A-$6.11
VYGR-$98.71M-$107.73MN/A-$1.81
ARMP-$168.97M-$192.18MN/A-$5.31
View Top Biotech Stocks

Protalix Biotherapeutics Earnings Reports & History FAQ

What were Protalix Biotherapeutics's earnings last quarter?

On PLX's earnings call on Aug 12, 2026, Protalix Biotherapeutics (NYSEMKT: PLX) reported Q2 2026 earnings per share (EPS) of $0.05, up Infinity% year over year. Total PLX earnings for the quarter were $3.78 million. In the same quarter last year, Protalix Biotherapeutics's earnings per share (EPS) was $0.00.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.

Is Protalix Biotherapeutics profitable or losing money?

As of the last Protalix Biotherapeutics earnings report, Protalix Biotherapeutics is currently profitable. Protalix Biotherapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $18.95 million, a 201.91% increase year over year.

What was PLX's earnings growth in the past year?

As of Protalix Biotherapeutics's earnings date in Aug 12, 2026, Protalix Biotherapeutics's earnings has grown 200% year over year. This is 182.81 percentage points higher than the US Biotechnology industry earnings growth rate of 17.19%. PLX earnings in the past year totalled $18.95 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.